{"id":342263,"date":"2025-08-20T17:25:53","date_gmt":"2025-08-20T17:25:53","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-axsome-therapeutics\/"},"modified":"2025-08-20T17:25:53","modified_gmt":"2025-08-20T17:25:53","slug":"how-to-buy-axsome-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/","title":{"rendered":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-342263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - AXSM Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - AXSM Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Axsome Therapeutics (AXSM) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve biyoteknoloji hisse senedi ba\u015far\u0131s\u0131 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Axsome Therapeutics (AXSM) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat analizini, 2025-2030 tahminlerini ve biyoteknoloji hisse senedi ba\u015far\u0131s\u0131 i\u00e7in ad\u0131m ad\u0131m yat\u0131r\u0131m stratejilerini \u00f6\u011frenin."},"intro":"N\u00f6robilim tedavisinin kurallar\u0131n\u0131 yeniden yazan bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Axsome Therapeutics (AXSM), t\u0131bbi yenilik ile finansal f\u0131rsat\u0131n heyecan verici kesi\u015fimini temsil ediyor. Depresyon, migren ve uyku bozukluklar\u0131 i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle, bu \u015firket yat\u0131r\u0131mc\u0131lara hayat de\u011fi\u015ftiren t\u0131bbi geli\u015fmelere kat\u0131lma ve sermayelerini b\u00fcy\u00fctme \u015fans\u0131 sunuyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"N\u00f6robilim tedavisinin kurallar\u0131n\u0131 yeniden yazan bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Axsome Therapeutics (AXSM), t\u0131bbi yenilik ile finansal f\u0131rsat\u0131n heyecan verici kesi\u015fimini temsil ediyor. Depresyon, migren ve uyku bozukluklar\u0131 i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedavilerle, bu \u015firket yat\u0131r\u0131mc\u0131lara hayat de\u011fi\u015ftiren t\u0131bbi geli\u015fmelere kat\u0131lma ve sermayelerini b\u00fcy\u00fctme \u015fans\u0131 sunuyor."},"body_html":"<h2>\ud83d\udcc8 AXSM Hisse Senedi Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla Axsome Therapeutics (AXSM), NASDAQ borsas\u0131nda <strong>111,29 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Bu fiyat, yat\u0131r\u0131mc\u0131lar i\u00e7in ilgin\u00e7 bir an\u0131 temsil ediyor\u2014hisse senedi 52 haftal\u0131k en y\u00fcksek seviyesi olan 139,13 $'\u0131n yakla\u015f\u0131k %25 alt\u0131nda ancak y\u0131ll\u0131k en d\u00fc\u015f\u00fck seviyesi 75,56 $'\u0131n %32 \u00fczerinde sa\u011flam bir konumda.<\/p> <p><strong>Takviminize not edin: Kas\u0131m 2025 kritik.<\/strong> Axsome'un 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik duyurular \u00f6nemli fiyat hareketlerine neden oldu ve bu tarih hem giri\u015f hem de \u00e7\u0131k\u0131\u015f zamanlamas\u0131 kararlar\u0131 i\u00e7in \u00e7ok \u00f6nemli.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>\u00d6nceki kazan\u00e7 raporlar\u0131n\u0131n AXSM hissesini nas\u0131l etkiledi\u011fine bakal\u0131m:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>4 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>105-108 $ aral\u0131\u011f\u0131<\/td><td>%3-5 art\u0131\u015f (beklentileri a\u015ft\u0131)<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>98-102 $ aral\u0131\u011f\u0131<\/td><td>%8-12 art\u0131\u015f (g\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi)<\/td><\/tr> <tr><td>\u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>92-95 $ aral\u0131\u011f\u0131<\/td><td>%15-18 art\u0131\u015f (pipeline heyecan\u0131)<\/td><\/tr> <tr><td>Kas 2024<\/td><td>\u00dcr\u00fcn Lansman\u0131<\/td><td>85-88 $ aral\u0131\u011f\u0131<\/td><td>%6-8 art\u0131\u015f (pazar geni\u015flemesi)<\/td><\/tr> <tr><td>A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>80-83 $ aral\u0131\u011f\u0131<\/td><td>%4-6 azal\u0131\u015f (hedeflerin biraz alt\u0131nda)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle AXSM'yi %5-15 art\u0131r\u0131rken, k\u00fc\u00e7\u00fck ka\u00e7\u0131rmalar ge\u00e7ici %3-8 d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temel ve pipeline potansiyeli sayesinde s\u00fcrekli toparlan\u0131r.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3> <p>AXSM hisseleri bu d\u00f6nemde ola\u011fan\u00fcst\u00fc diren\u00e7 ve b\u00fcy\u00fcme g\u00f6sterdi:<\/p> <ul> <li><strong>Mart 2025<\/strong>: 95-100 $ aral\u0131\u011f\u0131 (4. \u00e7eyrek sonras\u0131 konsolidasyon)<\/li> <li><strong>Nisan 2025<\/strong>: 102-108 $ (SYMBRAVO onay\u0131 beklentisi)<\/li> <li><strong>May\u0131s 2025<\/strong>: 110-115 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131 + %62 gelir art\u0131\u015f\u0131)<\/li> <li><strong>Haziran 2025<\/strong>: 118-125 $ (SYMBRAVO ticari lansman ba\u015far\u0131s\u0131)<\/li> <li><strong>Temmuz 2025<\/strong>: 120-128 $ (NASDAQ zil \u00e7alma etkinli\u011fi + Ar-Ge g\u00fcn\u00fc)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 105-112 $ (2. \u00e7eyrek kar realizasyonu + piyasa volatilitesi)<\/li> <\/ul> <p><strong>Genel y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p> <ul> <li>Rekor gelir b\u00fcy\u00fcmesi: 1. \u00e7eyrekte y\u0131ll\u0131k %62, 2. \u00e7eyrekte y\u0131ll\u0131k %72<\/li> <li>Ba\u015far\u0131l\u0131 SYMBRAVO migren tedavisi lansman\u0131<\/li> <li>Birden fazla Faz 3 deneme ilerlemesi<\/li> <li>T\u00fcm \u00fcr\u00fcnlerde pazar eri\u015fiminin geni\u015flemesi<\/li> <\/ul> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve pipeline geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 140-160 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %25-40 y\u00fckseli\u015f)<br> Analistler \"G\u00fc\u00e7l\u00fc Al\" derecesini koruyor ve ortalama fiyat hedefleri 176-178 $ civar\u0131nda, ancak daha temkinli tahminler mevcut piyasa ko\u015fullar\u0131nda 140-150 $ aral\u0131\u011f\u0131n\u0131 m\u00fcmk\u00fcn g\u00f6r\u00fcyor.<\/li> <li><strong>2026 Tahmini<\/strong>: 180-220 $<br> Bu projeksiyon, Alzheimer ajitasyonu i\u00e7in AXS-05 ve narkolepsi i\u00e7in AXS-12'nin ba\u015far\u0131l\u0131 NDA onaylar\u0131n\u0131 ve mevcut \u00fcr\u00fcnlerden devam eden gelir b\u00fcy\u00fcmesini varsay\u0131yor.<\/li> <li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 250-350 $<br> 2028'e kadar birden fazla yeni \u00fcr\u00fcn lansman\u0131 ve uluslararas\u0131 pazarlara potansiyel geni\u015fleme bekleniyor, bu da \u00f6nemli gelir \u00e7e\u015fitlendirmesi sa\u011flayacak.<\/li> <li><strong>2030 Uzun Vadeli Vizyon<\/strong>: 400-600 $<br> Axsome pipeline stratejisini ba\u015far\u0131yla uygular ve hedefledi\u011fi 150+ milyon hasta pazar\u0131n\u0131n sadece bir k\u0131sm\u0131n\u0131 yakalarsa, hisseler ola\u011fan\u00fcst\u00fc uzun vadeli getiri sa\u011flayabilir.<\/li> <\/ul> <p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar Kas\u0131m ay\u0131ndaki olas\u0131 kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri beklemeli.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Mevcut ba\u015far\u0131ya ra\u011fmen, herhangi bir Faz 3 deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 hisseyi an\u0131nda %30-50 d\u00fc\u015f\u00fcrebilir. Biyoteknoloji sekt\u00f6r\u00fc klinik sonu\u00e7lar etraf\u0131nda olduk\u00e7a volatil.<\/li> <li><strong>FDA D\u00fczenleyici Engelleri<\/strong>: Ba\u015far\u0131l\u0131 denemelere ra\u011fmen FDA reddi veya gecikmeleri hisse fiyatlar\u0131n\u0131 y\u0131k\u0131c\u0131 \u015fekilde etkileyebilir. Son d\u00f6nemde \u00f6nemli FDA yetkililerinin ayr\u0131lmas\u0131 belirsizlik yarat\u0131yor (<a href=\"https:\/\/www.pharmavoice.com\/news\/biotech-market-ipos-manda-stocks-pharma\/745288\/\">PharmaVoice<\/a>).<\/li> <li><strong>Rekabetin Artmas\u0131<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri, pazar pay\u0131n\u0131 azaltabilecek rakip n\u00f6robilim tedavileri geli\u015ftiriyor.<\/li> <li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: Gelir etkileyici \u015fekilde b\u00fcy\u00fcrken, \u015firket hala zarar ediyor (-246,9M $ TTM). S\u00fcrekli zararlar ek finansman gerektirir ve bu da hissedar de\u011ferini seyreltebilir.<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Patlay\u0131c\u0131 Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrekte %72 y\u0131ll\u0131k b\u00fcy\u00fcme g\u00fc\u00e7l\u00fc ticari uygulamay\u0131 g\u00f6steriyor (<a href=\"https:\/\/www.biospace.com\/press-releases\/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update\">BioSpace<\/a>).<\/li> <li><strong>Pipeline Momentum<\/strong>: 2025 4. \u00e7eyrekte sigaray\u0131 b\u0131rakma ve pediatrik DEHB dahil b\u00fcy\u00fck endikasyonlarda d\u00f6rt ek Faz 3 denemesi ba\u015flat\u0131l\u0131yor.<\/li> <li><strong>Pazar Geni\u015flemesi<\/strong>: SYMBRAVO'nun Haziran 2025 ticari lansman\u0131, AUVELITY'nin ba\u015far\u0131s\u0131n\u0131 tamamlayan ek bir gelir ak\u0131\u015f\u0131 sa\u011fl\u0131yor.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: N\u00f6robilim tedavileri, artan sigorta kapsam\u0131 ve hasta talebi ile en h\u0131zl\u0131 b\u00fcy\u00fcyen ila\u00e7 sekt\u00f6rlerinden biri.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Stratejik Giri\u015f Noktalar\u0131<\/strong>:<\/p> <ol> <li>Dolar maliyeti ortalamas\u0131 kullan\u0131n\u2014piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li>Daha iyi giri\u015f fiyatlar\u0131 i\u00e7in 105-108 $ seviyelerinde al\u0131m emirleri belirleyin<\/li> <li>Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'undan fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <\/ol> <p><strong>Risk Y\u00f6netimi Temelleri<\/strong>:<\/p> <ul> <li>Giri\u015f noktalar\u0131n\u0131n %15-20 alt\u0131nda stop-loss emirleri koyun<\/li> <li>%25-30 kazan\u00e7ta k\u00e2r\u0131n bir k\u0131sm\u0131n\u0131 realize edin<\/li> <li>Yakla\u015fan FDA karar tarihlerini takip edin<\/li> <\/ul> <p><strong>Esprili yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/strong>: \"Biyoteknoloji hisseleriyle i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Her zaman koruyucu g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc tak\u0131n!\"<\/p> <h2>\u2705 Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir hisse senedi i\u015flem platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve kesirli hisse imkan\u0131 sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Platformu \u00f6\u011frenmek i\u00e7in 50-100 $ ile ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>AXSM temel analizini yap\u0131n<\/td><td>Gelir b\u00fcy\u00fcmesi, pipeline durumu ve analist derecelendirmelerini inceleyin<\/td><\/tr> <tr><td>4<\/td><td>Fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><td>\u00d6nemli destek seviyelerinde (105 $, 100 $, 95 $) bildirim al\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limit emri verin<\/td><td>Piyasa fiyat\u0131 yerine hedef fiyat\u0131n\u0131zdan sat\u0131n al\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonunuzu d\u00fczenli izleyin<\/td><td>Kazan\u00e7 tarihleri ve klinik deneme kilometre ta\u015flar\u0131n\u0131 takip edin<\/td><\/tr> <tr><td>7<\/td><td>Risk y\u00f6netimini uygulay\u0131n<\/td><td>Hemen stop-loss ve kar al seviyeleri belirleyin<\/td><\/tr> <tr><td>8<\/td><td>\u00c7eyreklik raporlar\u0131 g\u00f6zden ge\u00e7irin<\/td><td>Gelir b\u00fcy\u00fcmesi ve pipeline ilerlemesi hakk\u0131nda g\u00fcncel kal\u0131n<\/td><\/tr> <tr><td>9<\/td><td>Temett\u00fc yeniden yat\u0131r\u0131m\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td><td>Sunuluyorsa, getirilerinizi otomatik olarak bile\u015ftirin<\/td><\/tr> <tr><td>10<\/td><td>D\u00fczenli olarak portf\u00f6y\u00fc dengeleyin<\/td><td>Portf\u00f6y de\u011feri de\u011fi\u015ftik\u00e7e pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni AXSM Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Axsome Therapeutics ile ba\u015flamay\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li> <li><strong>1 dakikal\u0131k KYC do\u011frulamas\u0131<\/strong>\u2014herhangi bir resmi kimlikle h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong>\u2014kripto, e-c\u00fczdan ve geleneksel y\u00f6ntemlerde esneklik<\/li> <li><strong>Kesirli hisse eri\u015fimi<\/strong>\u2014k\u00fc\u00e7\u00fck hesaplarla bile AXSM hisselerinin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014AXSM fiyat hareketlerini takip edin ve anl\u0131k uyar\u0131lar ayarlay\u0131n<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, geleneksel arac\u0131 hesaplar\u0131n karma\u015f\u0131kl\u0131\u011f\u0131 olmadan biyoteknoloji yat\u0131r\u0131mlar\u0131na kat\u0131lmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Axsome Therapeutics: N\u00f6robilimde Yenilik Lideri<\/h2> <p>Axsome Therapeutics, merkezi sinir sistemi tedavi yenili\u011finde \u00f6nc\u00fc konumdad\u0131r. \u015eirket \u015fu anda depresyon i\u00e7in AUVELITY ve uyku bozukluklar\u0131 i\u00e7in SUNOSI olmak \u00fczere iki ba\u015far\u0131l\u0131 \u00fcr\u00fcn\u00fc pazarlamakta olup, SYMBRAVO ise yak\u0131n zamanda akut migren tedavisi i\u00e7in piyasaya s\u00fcr\u00fclm\u00fc\u015ft\u00fcr.<\/p> <p>\u015eirketin pipeline'\u0131, n\u00f6robilim sekt\u00f6r\u00fcndeki en sa\u011flamlardan biridir; fibromiyalji (AXS-14) i\u00e7in NDA ba\u015fvurular\u0131 yap\u0131lm\u0131\u015f ve Alzheimer ajitasyonu (AXS-05) ile narkolepsi (AXS-12) i\u00e7in planlanan ba\u015fvurular bulunmaktad\u0131r. Ar-Ge stratejileri yaln\u0131zca ABD'de 150 milyondan fazla hastay\u0131 etkileyen durumlar\u0131 hedefleyerek muazzam pazar potansiyeli sunmaktad\u0131r.<\/p> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Axsome, 21 Temmuz'da NASDAQ a\u00e7\u0131l\u0131\u015f zilini \u00e7alarak man\u015fetlere \u00e7\u0131kt\u0131\u2014ancak bir farkla. CEO Herriot Tabuteau'nun sadece yo\u011funla\u015fm\u0131\u015f d\u00fc\u015f\u00fcnceleriyle zili \u00e7almas\u0131n\u0131 sa\u011flayan beyin dalgas\u0131 okuma teknolojisi kullan\u0131ld\u0131; bu, sadece ila\u00e7lar\u0131n \u00f6tesinde n\u00f6robilim yenili\u011fine ba\u011fl\u0131l\u0131klar\u0131n\u0131 g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AXSM Hisse Senedi Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla Axsome Therapeutics (AXSM), NASDAQ borsas\u0131nda <strong>111,29 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Bu fiyat, yat\u0131r\u0131mc\u0131lar i\u00e7in ilgin\u00e7 bir an\u0131 temsil ediyor\u2014hisse senedi 52 haftal\u0131k en y\u00fcksek seviyesi olan 139,13 $&#8217;\u0131n yakla\u015f\u0131k %25 alt\u0131nda ancak y\u0131ll\u0131k en d\u00fc\u015f\u00fck seviyesi 75,56 $&#8217;\u0131n %32 \u00fczerinde sa\u011flam bir konumda.<\/p>\n<p><strong>Takviminize not edin: Kas\u0131m 2025 kritik.<\/strong> Axsome&#8217;un 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor. Tarihsel olarak, bu \u00e7eyreklik duyurular \u00f6nemli fiyat hareketlerine neden oldu ve bu tarih hem giri\u015f hem de \u00e7\u0131k\u0131\u015f zamanlamas\u0131 kararlar\u0131 i\u00e7in \u00e7ok \u00f6nemli.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>\u00d6nceki kazan\u00e7 raporlar\u0131n\u0131n AXSM hissesini nas\u0131l etkiledi\u011fine bakal\u0131m:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>4 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>105-108 $ aral\u0131\u011f\u0131<\/td>\n<td>%3-5 art\u0131\u015f (beklentileri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>98-102 $ aral\u0131\u011f\u0131<\/td>\n<td>%8-12 art\u0131\u015f (g\u00fc\u00e7l\u00fc gelir b\u00fcy\u00fcmesi)<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>92-95 $ aral\u0131\u011f\u0131<\/td>\n<td>%15-18 art\u0131\u015f (pipeline heyecan\u0131)<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>\u00dcr\u00fcn Lansman\u0131<\/td>\n<td>85-88 $ aral\u0131\u011f\u0131<\/td>\n<td>%6-8 art\u0131\u015f (pazar geni\u015flemesi)<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>80-83 $ aral\u0131\u011f\u0131<\/td>\n<td>%4-6 azal\u0131\u015f (hedeflerin biraz alt\u0131nda)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle AXSM&#8217;yi %5-15 art\u0131r\u0131rken, k\u00fc\u00e7\u00fck ka\u00e7\u0131rmalar ge\u00e7ici %3-8 d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temel ve pipeline potansiyeli sayesinde s\u00fcrekli toparlan\u0131r.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3>\n<p>AXSM hisseleri bu d\u00f6nemde ola\u011fan\u00fcst\u00fc diren\u00e7 ve b\u00fcy\u00fcme g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: 95-100 $ aral\u0131\u011f\u0131 (4. \u00e7eyrek sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Nisan 2025<\/strong>: 102-108 $ (SYMBRAVO onay\u0131 beklentisi)<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 110-115 $ (1. \u00e7eyrek kazan\u00e7lar\u0131 beklentiyi a\u015ft\u0131 + %62 gelir art\u0131\u015f\u0131)<\/li>\n<li><strong>Haziran 2025<\/strong>: 118-125 $ (SYMBRAVO ticari lansman ba\u015far\u0131s\u0131)<\/li>\n<li><strong>Temmuz 2025<\/strong>: 120-128 $ (NASDAQ zil \u00e7alma etkinli\u011fi + Ar-Ge g\u00fcn\u00fc)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 105-112 $ (2. \u00e7eyrek kar realizasyonu + piyasa volatilitesi)<\/li>\n<\/ul>\n<p><strong>Genel y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p>\n<ul>\n<li>Rekor gelir b\u00fcy\u00fcmesi: 1. \u00e7eyrekte y\u0131ll\u0131k %62, 2. \u00e7eyrekte y\u0131ll\u0131k %72<\/li>\n<li>Ba\u015far\u0131l\u0131 SYMBRAVO migren tedavisi lansman\u0131<\/li>\n<li>Birden fazla Faz 3 deneme ilerlemesi<\/li>\n<li>T\u00fcm \u00fcr\u00fcnlerde pazar eri\u015fiminin geni\u015flemesi<\/li>\n<\/ul>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve pipeline geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 140-160 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %25-40 y\u00fckseli\u015f)<br \/> Analistler &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecesini koruyor ve ortalama fiyat hedefleri 176-178 $ civar\u0131nda, ancak daha temkinli tahminler mevcut piyasa ko\u015fullar\u0131nda 140-150 $ aral\u0131\u011f\u0131n\u0131 m\u00fcmk\u00fcn g\u00f6r\u00fcyor.<\/li>\n<li><strong>2026 Tahmini<\/strong>: 180-220 $<br \/> Bu projeksiyon, Alzheimer ajitasyonu i\u00e7in AXS-05 ve narkolepsi i\u00e7in AXS-12&#8217;nin ba\u015far\u0131l\u0131 NDA onaylar\u0131n\u0131 ve mevcut \u00fcr\u00fcnlerden devam eden gelir b\u00fcy\u00fcmesini varsay\u0131yor.<\/li>\n<li><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 250-350 $<br \/> 2028&#8217;e kadar birden fazla yeni \u00fcr\u00fcn lansman\u0131 ve uluslararas\u0131 pazarlara potansiyel geni\u015fleme bekleniyor, bu da \u00f6nemli gelir \u00e7e\u015fitlendirmesi sa\u011flayacak.<\/li>\n<li><strong>2030 Uzun Vadeli Vizyon<\/strong>: 400-600 $<br \/> Axsome pipeline stratejisini ba\u015far\u0131yla uygular ve hedefledi\u011fi 150+ milyon hasta pazar\u0131n\u0131n sadece bir k\u0131sm\u0131n\u0131 yakalarsa, hisseler ola\u011fan\u00fcst\u00fc uzun vadeli getiri sa\u011flayabilir.<\/li>\n<\/ul>\n<p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar Kas\u0131m ay\u0131ndaki olas\u0131 kazan\u00e7 sonras\u0131 d\u00fc\u015f\u00fc\u015fleri beklemeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Mevcut ba\u015far\u0131ya ra\u011fmen, herhangi bir Faz 3 deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 hisseyi an\u0131nda %30-50 d\u00fc\u015f\u00fcrebilir. Biyoteknoloji sekt\u00f6r\u00fc klinik sonu\u00e7lar etraf\u0131nda olduk\u00e7a volatil.<\/li>\n<li><strong>FDA D\u00fczenleyici Engelleri<\/strong>: Ba\u015far\u0131l\u0131 denemelere ra\u011fmen FDA reddi veya gecikmeleri hisse fiyatlar\u0131n\u0131 y\u0131k\u0131c\u0131 \u015fekilde etkileyebilir. Son d\u00f6nemde \u00f6nemli FDA yetkililerinin ayr\u0131lmas\u0131 belirsizlik yarat\u0131yor (<a href=\"https:\/\/www.pharmavoice.com\/news\/biotech-market-ipos-manda-stocks-pharma\/745288\/\">PharmaVoice<\/a>).<\/li>\n<li><strong>Rekabetin Artmas\u0131<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri, pazar pay\u0131n\u0131 azaltabilecek rakip n\u00f6robilim tedavileri geli\u015ftiriyor.<\/li>\n<li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: Gelir etkileyici \u015fekilde b\u00fcy\u00fcrken, \u015firket hala zarar ediyor (-246,9M $ TTM). S\u00fcrekli zararlar ek finansman gerektirir ve bu da hissedar de\u011ferini seyreltebilir.<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Patlay\u0131c\u0131 Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrekte %72 y\u0131ll\u0131k b\u00fcy\u00fcme g\u00fc\u00e7l\u00fc ticari uygulamay\u0131 g\u00f6steriyor (<a href=\"https:\/\/www.biospace.com\/press-releases\/axsome-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update\">BioSpace<\/a>).<\/li>\n<li><strong>Pipeline Momentum<\/strong>: 2025 4. \u00e7eyrekte sigaray\u0131 b\u0131rakma ve pediatrik DEHB dahil b\u00fcy\u00fck endikasyonlarda d\u00f6rt ek Faz 3 denemesi ba\u015flat\u0131l\u0131yor.<\/li>\n<li><strong>Pazar Geni\u015flemesi<\/strong>: SYMBRAVO&#8217;nun Haziran 2025 ticari lansman\u0131, AUVELITY&#8217;nin ba\u015far\u0131s\u0131n\u0131 tamamlayan ek bir gelir ak\u0131\u015f\u0131 sa\u011fl\u0131yor.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: N\u00f6robilim tedavileri, artan sigorta kapsam\u0131 ve hasta talebi ile en h\u0131zl\u0131 b\u00fcy\u00fcyen ila\u00e7 sekt\u00f6rlerinden biri.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Stratejik Giri\u015f Noktalar\u0131<\/strong>:<\/p>\n<ol>\n<li>Dolar maliyeti ortalamas\u0131 kullan\u0131n\u2014piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li>Daha iyi giri\u015f fiyatlar\u0131 i\u00e7in 105-108 $ seviyelerinde al\u0131m emirleri belirleyin<\/li>\n<li>Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;undan fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<\/ol>\n<p><strong>Risk Y\u00f6netimi Temelleri<\/strong>:<\/p>\n<ul>\n<li>Giri\u015f noktalar\u0131n\u0131n %15-20 alt\u0131nda stop-loss emirleri koyun<\/li>\n<li>%25-30 kazan\u00e7ta k\u00e2r\u0131n bir k\u0131sm\u0131n\u0131 realize edin<\/li>\n<li>Yakla\u015fan FDA karar tarihlerini takip edin<\/li>\n<\/ul>\n<p><strong>Esprili yat\u0131r\u0131mc\u0131 bilgeli\u011fi<\/strong>: &#8220;Biyoteknoloji hisseleriyle i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Her zaman koruyucu g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc tak\u0131n!&#8221;<\/p>\n<h2>\u2705 Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir hisse senedi i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve kesirli hisse imkan\u0131 sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Platformu \u00f6\u011frenmek i\u00e7in 50-100 $ ile ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>AXSM temel analizini yap\u0131n<\/td>\n<td>Gelir b\u00fcy\u00fcmesi, pipeline durumu ve analist derecelendirmelerini inceleyin<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<td>\u00d6nemli destek seviyelerinde (105 $, 100 $, 95 $) bildirim al\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit emri verin<\/td>\n<td>Piyasa fiyat\u0131 yerine hedef fiyat\u0131n\u0131zdan sat\u0131n al\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu d\u00fczenli izleyin<\/td>\n<td>Kazan\u00e7 tarihleri ve klinik deneme kilometre ta\u015flar\u0131n\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Risk y\u00f6netimini uygulay\u0131n<\/td>\n<td>Hemen stop-loss ve kar al seviyeleri belirleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u00c7eyreklik raporlar\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Gelir b\u00fcy\u00fcmesi ve pipeline ilerlemesi hakk\u0131nda g\u00fcncel kal\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Temett\u00fc yeniden yat\u0131r\u0131m\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Sunuluyorsa, getirilerinizi otomatik olarak bile\u015ftirin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>D\u00fczenli olarak portf\u00f6y\u00fc dengeleyin<\/td>\n<td>Portf\u00f6y de\u011feri de\u011fi\u015ftik\u00e7e pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni AXSM Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Axsome Therapeutics ile ba\u015flamay\u0131 d\u00fc\u015f\u00fcnenler i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc eri\u015filebilirlik sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li>\n<li><strong>1 dakikal\u0131k KYC do\u011frulamas\u0131<\/strong>\u2014herhangi bir resmi kimlikle h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong>\u2014kripto, e-c\u00fczdan ve geleneksel y\u00f6ntemlerde esneklik<\/li>\n<li><strong>Kesirli hisse eri\u015fimi<\/strong>\u2014k\u00fc\u00e7\u00fck hesaplarla bile AXSM hisselerinin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014AXSM fiyat hareketlerini takip edin ve anl\u0131k uyar\u0131lar ayarlay\u0131n<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, geleneksel arac\u0131 hesaplar\u0131n karma\u015f\u0131kl\u0131\u011f\u0131 olmadan biyoteknoloji yat\u0131r\u0131mlar\u0131na kat\u0131lmak isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Axsome Therapeutics: N\u00f6robilimde Yenilik Lideri<\/h2>\n<p>Axsome Therapeutics, merkezi sinir sistemi tedavi yenili\u011finde \u00f6nc\u00fc konumdad\u0131r. \u015eirket \u015fu anda depresyon i\u00e7in AUVELITY ve uyku bozukluklar\u0131 i\u00e7in SUNOSI olmak \u00fczere iki ba\u015far\u0131l\u0131 \u00fcr\u00fcn\u00fc pazarlamakta olup, SYMBRAVO ise yak\u0131n zamanda akut migren tedavisi i\u00e7in piyasaya s\u00fcr\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n<p>\u015eirketin pipeline&#8217;\u0131, n\u00f6robilim sekt\u00f6r\u00fcndeki en sa\u011flamlardan biridir; fibromiyalji (AXS-14) i\u00e7in NDA ba\u015fvurular\u0131 yap\u0131lm\u0131\u015f ve Alzheimer ajitasyonu (AXS-05) ile narkolepsi (AXS-12) i\u00e7in planlanan ba\u015fvurular bulunmaktad\u0131r. Ar-Ge stratejileri yaln\u0131zca ABD&#8217;de 150 milyondan fazla hastay\u0131 etkileyen durumlar\u0131 hedefleyerek muazzam pazar potansiyeli sunmaktad\u0131r.<\/p>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Axsome, 21 Temmuz&#8217;da NASDAQ a\u00e7\u0131l\u0131\u015f zilini \u00e7alarak man\u015fetlere \u00e7\u0131kt\u0131\u2014ancak bir farkla. CEO Herriot Tabuteau&#8217;nun sadece yo\u011funla\u015fm\u0131\u015f d\u00fc\u015f\u00fcnceleriyle zili \u00e7almas\u0131n\u0131 sa\u011flayan beyin dalgas\u0131 okuma teknolojisi kullan\u0131ld\u0131; bu, sadece ila\u00e7lar\u0131n \u00f6tesinde n\u00f6robilim yenili\u011fine ba\u011fl\u0131l\u0131klar\u0131n\u0131 g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Axsome Therapeutics hisseleri nereden al\u0131nabilir?","answer":"AXSM hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"AXSM hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"Dolar maliyeti ortalamas\u0131 kullanmak, fiyat uyar\u0131lar\u0131 ayarlamak ve portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'unu biyoteknoloji hisselerine ay\u0131rmak iyi bir ba\u015flang\u0131\u00e7 stratejisidir."},{"question":"Axsome Therapeutics'in gelecekteki fiyat tahmini nedir?","answer":"Analistlerin 2025 y\u0131l sonu hedefi 140-160 $ aral\u0131\u011f\u0131nda olup, 2030 i\u00e7in 400-600 $ aras\u0131nda uzun vadeli bir b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Axsome Therapeutics hisseleri hangi riskleri ta\u015f\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay s\u00fcre\u00e7lerindeki gecikmeler, artan rekabet ve mali s\u00fcrd\u00fcr\u00fclebilirlik riskleri mevcuttur."},{"question":"Yeni ba\u015flayanlar AXSM hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"D\u00fc\u015f\u00fck miktarlarla ba\u015flayarak, stop-loss emirleri koyarak ve FDA karar tarihlerini takip ederek risk y\u00f6netimi yapmalar\u0131 \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Axsome Therapeutics hisseleri nereden al\u0131nabilir?","answer":"AXSM hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"AXSM hisseleri i\u00e7in en iyi yat\u0131r\u0131m stratejisi nedir?","answer":"Dolar maliyeti ortalamas\u0131 kullanmak, fiyat uyar\u0131lar\u0131 ayarlamak ve portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'unu biyoteknoloji hisselerine ay\u0131rmak iyi bir ba\u015flang\u0131\u00e7 stratejisidir."},{"question":"Axsome Therapeutics'in gelecekteki fiyat tahmini nedir?","answer":"Analistlerin 2025 y\u0131l sonu hedefi 140-160 $ aral\u0131\u011f\u0131nda olup, 2030 i\u00e7in 400-600 $ aras\u0131nda uzun vadeli bir b\u00fcy\u00fcme \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Axsome Therapeutics hisseleri hangi riskleri ta\u015f\u0131r?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay s\u00fcre\u00e7lerindeki gecikmeler, artan rekabet ve mali s\u00fcrd\u00fcr\u00fclebilirlik riskleri mevcuttur."},{"question":"Yeni ba\u015flayanlar AXSM hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"D\u00fc\u015f\u00fck miktarlarla ba\u015flayarak, stop-loss emirleri koyarak ve FDA karar tarihlerini takip ederek risk y\u00f6netimi yapmalar\u0131 \u00f6nerilir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T17:25:53+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T17:25:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\",\"name\":\"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-20T17:25:53+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T17:25:53+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T17:25:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/","name":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r - Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-20T17:25:53+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-axsome-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Axsome Therapeutics, Inc. (AXSM) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Axsome Therapeutics, Inc. (AXSM) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":342267,"slug":"how-to-buy-axsome-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Axsome Therapeutics, Inc. (AXSM) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Axsome Therapeutics, Inc. (AXSM)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-axsome-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":342260,"slug":"how-to-buy-axsome-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Axsome Therapeutics, Inc. (AXSM) - Investimento em a\u00e7\u00f5es da Axsome Therapeutics, Inc. (AXSM)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-axsome-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=342263"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342263\/revisions"}],"predecessor-version":[{"id":342264,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342263\/revisions\/342264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=342263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=342263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=342263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}